陈烈,刘霖,王智超,张继龙,朱梦莉

• 1:湖北省武汉市中西结合医院

摘要(Abstract)：

目的观察参附注射液联合去甲肾上腺素对内毒素诱导的脓毒症休克大鼠sCD163、丙二醛、超氧化物歧化酶的影响,探讨参附注射液对脓毒症休克的可能作用机制。方法 SD大鼠60只,制作脓毒症休克大鼠模型,观察给予药物治疗后大鼠血清sCD163、丙二醛、超氧化物歧化酶的变化。结果空白组给药后1、6、18 h sCD163含量与给药前比较变化不明显(均P>0.05)。模型组1、6、18 h sCD163含量与给药前比较,均升高(均P<0.05)。西药组、参附组、西药加参附组sCD163含量给药后与给药前比较,均下降(均P<0.05)。各组给药后sCD163含量与模型组给药后同期比较,差异均有统计学意义(均P<0.05)。西药加参附组给药后sCD163含量与西药组、参附组两组同期比较,差异均有统计学意义(均P<0.05)。造模后模型组、西药组、参附组、西药加参附组超氧化物歧化酶含量与空白对照组比较明显下降(均P<0.05);丙二醛含量则均明显升高(均P<0.05)。西药组、参附组、西药加参附组给药后18 h超氧化物歧化酶含量与模型组同期比较均升高(均P<0.05);而丙二醛含量与模型组同期比较均下降(均P<0.05)。且西药加参附组的超氧化物歧化酶含量高于同期单纯西药组、参附组(均P<0.05);而丙二醛含量则低于同期单纯西药组、参附组(均P<0.05)。结论参附注射液对脓毒症休克大鼠具有抗氧化作用,sCD163可作为脓毒症的诊断指标及疗效评价指标。

关键词(KeyWords)： 脓毒症休克;参附注射液;sCD163;丙二醛;超氧化物歧化酶

Abstract:

Keywords:

基金项目(Foundation): 武汉市卫计委科研资助项目(WZ14A05)

作者(Author): 陈烈,刘霖,王智超,张继龙,朱梦莉

参考文献(References)：

• [1]Moore LJ,Mckinley BA,Turner KL,et al.The epidemiology o sepsis in general surgery patients[J].J Trauma,2011,70(3):672-680.
• [2]梁宇,孙立东,赵子瑜,等.大剂量参附注射液治疗脓毒性休克的临床疗效分析[J].中国中西医结合急救杂志,2012,19(2):109-110.
• [3]杨靖,赵若琪,谢雁鸣,等.基于HIS真实世界的参附注射液临床实效研究[J].中国中药杂志,2012,37(18):2730-2734.
• [4]王常青,任海伟,王海凤,等.黑豆多肽对D-半乳糖衰老小鼠抗氧化能力的影响[J].食品科学,2010,31(3):262-266
• [5]程云辉,文新华,王璋.麦胚蛋白酶解物对小鼠抗氧化作用的研究[J].食品科学,2007,28(7):486-489.
• [6]郑世营,张晓膺.参附注射液对离体大鼠缺氧/复氧心肌的保护作用[J].中国急救医学,2004,6(24):425-427.
• [7]郑虎昆.中药现代研究与应用[M].北京:学苑出版社,1997:109-110.
• [8]Blanco J,Muriel-Bombin A,Sagredo V,et al.Incidence,organ dysfunction and mortality in severe sepsis:a Spanishmulticentre study[J].Crit Care,2008,12(6):R158.
• [9]Sergio Vera,Rolando Martínez,Juan Guillermo Gormaz,et al Novel relationships between oxidative stress and angiogenesis-related factors in sepsis:New biomarkers and therapies[J].Ann Med,2015,47(4):289-300.
• [10]Bime C,Zhou T,Wang T,et al.Reactive oxygen speciesassociatedmolecular signature predicts survival in patients with sepsis[J].Pulm Circ,2016,6(2):196-201.
• [11]Santos SS,Brunialti MK,Rigato O,et al.Generation of nitri oxide and reactive oxygen species by neutrophils and monocytes from septic patients and association with outcomes[J]Shock,2012,38(1):18-23.
• [12]Dahl KN,Kalinowski A,Pekkan K.mechanobiol ogy and th microcirculation:cellula,nuclear and fluid mechanics[J]Microcirculation,2010,17:179-191.
• [13]Van del Heuvel MM,Tensen CP,Van As JH,et al.Regulation of CD163 on human macropgages:cross-linking of CD163 induces signaling an activation[J].J Leukoc Biol,1999,66(5):858-866.
• [14]Vam gorp H,Delputte PL,Nauwynck HJ.Scavenger recepto CD163,a Jack-of-all-trades and potential target for cell-directed therapy[J].Mol Immunol,2010,47(7/8):1650-1660.
• [15]Gaini S,Pedersen SS,Koldkaer OG,et al.NEW immunological serum markers in bacteraemia:anti-inflammatory solubl CD163,but not proniflammatory high mobility group-box1protein,is related to prognosis[J].Clin Exp Immunol,2008,151(3):423-431.
• [16]Thomsen HH,Mller HJ,Trolle C,et al.The macrophage lowgrade inflammation marker s CD163 is modulated by exogenoux sex steroids[J].Endocr Connect,2013,2(4):216-224.